Metagenomi, a US-based gene editing technology spinout of University of California, Berkeley, received $10m in additional series A financing from RA Capital Management to bring the round to $75m.
RA Capital is co-leading the round with chemical and pharmaceutical producer Bayer subsidiary Leaps by Bayer and venture capital fund Humboldt Fund.
The first tranche in November 2020 also featured Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital.
Founded in 2018, Metagenomi is working on DNA editing systems that will utilise Crispr technology to function more accurately than conventional methods.
Andrew Levin, managing director of RA Capital, will join Metagenomi’s board of directors. He said: “Metagenomi’s technology and deep scientific foundation in the field of metagenomics enables novel clinical solutions for patients as the company emerges as a new leader in the therapeutic editing field.
“Where most approaches and pipelines are built on a single system, Metagenomi’s diverse toolbox of gene editing systems will allow the company to match the best technology to unmet medical needs.”
– A version of this article first appeared on our sister site, Global Corporate Venturing.

US-based gene editing technology developer Metagenomi added $10m to a series A round featuring chemical and pharmaceutical producer Bayer yesterday, increasing it to $75m.

Investment manager RA Capital Management put up the extra cash and is co-leading the round with Bayer subsidiary Leaps by Bayer and venture capital fund Humboldt Fund. The November 2020 first close also featured Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital.

Founded in 2018 as a spinout of University of California, Berkeley, Metagenomi is working on DNA editing systems that will utilise Crispr technology to function more accurately than conventional methods.

RA Capital managing director Andrew Levin is join Metagenomi’s board of directors. He said: “Metagenomi’s technology and deep scientific foundation in the field of metagenomics enables novel clinical solutions for patients as the company emerges as a new leader in the therapeutic editing field.

“Where most approaches and pipelines are built on a single system, Metagenomi’s diverse toolbox of gene editing systems will allow the company to match the best technology to unmet medical needs.”